(NASDAQ: GRTS) Gritstone Bio's forecast annual revenue growth rate of 41.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Gritstone Bio's revenue in 2024 is $15,645,000.On average, 3 Wall Street analysts forecast GRTS's revenue for 2024 to be $5,689,035,198, with the lowest GRTS revenue forecast at $1,704,539,172, and the highest GRTS revenue forecast at $12,919,755,506. On average, 3 Wall Street analysts forecast GRTS's revenue for 2025 to be $9,376,702,555, with the lowest GRTS revenue forecast at $770,842,555, and the highest GRTS revenue forecast at $24,102,401,028.
In 2026, GRTS is forecast to generate $2,331,527,307 in revenue, with the lowest revenue forecast at $863,126,523 and the highest revenue forecast at $3,799,928,090.